These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 22356631

  • 1. Implementing treatment goals for successful long-term management of psoriasis.
    Mrowietz U.
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():12-20. PubMed ID: 22356631
    [Abstract] [Full Text] [Related]

  • 2. An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals.
    Mrowietz U, Kragballe K, Reich K, Griffiths CE, Gu Y, Wang Y, Rozzo SJ.
    Br J Dermatol; 2013 Feb; 168(2):374-80. PubMed ID: 22880843
    [Abstract] [Full Text] [Related]

  • 3. Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting.
    Mrowietz U, Kragballe K, Nast A, Reich K.
    J Eur Acad Dermatol Venereol; 2011 May; 25 Suppl 3():1-13. PubMed ID: 21470314
    [Abstract] [Full Text] [Related]

  • 4. Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus.
    Langley RG, Saurat JH, Reich K, Nail Psoriasis Delphi Expert Panel.
    J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):373-81. PubMed ID: 22151734
    [Abstract] [Full Text] [Related]

  • 5. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R.
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [Abstract] [Full Text] [Related]

  • 6. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S.
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [Abstract] [Full Text] [Related]

  • 7. A clinician's paradigm in the treatment of psoriasis.
    Lebwohl M.
    J Am Acad Dermatol; 2005 Jul; 53(1 Suppl 1):S59-69. PubMed ID: 15968265
    [Abstract] [Full Text] [Related]

  • 8. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M.
    J Dermatolog Treat; 2007 Jul; 18(6):341-50. PubMed ID: 18058494
    [Abstract] [Full Text] [Related]

  • 9. Treatment goals in psoriasis.
    Reich K, Mrowietz U.
    J Dtsch Dermatol Ges; 2007 Jul; 5(7):566-74. PubMed ID: 17610606
    [Abstract] [Full Text] [Related]

  • 10. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
    Noda S, Mizuno K, Adachi M.
    J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
    Sola-Ortigosa J, Sánchez-Regaña M, Umbert-Millet P.
    J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
    [Abstract] [Full Text] [Related]

  • 12. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis.
    Bagel J.
    J Drugs Dermatol; 2011 Apr; 10(4):366-71. PubMed ID: 21455546
    [Abstract] [Full Text] [Related]

  • 13. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J.
    Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
    [Abstract] [Full Text] [Related]

  • 14. Treatment of severe facial psoriasis with adalimumab.
    Noiles K, Vender R.
    J Drugs Dermatol; 2008 Dec; 7(12):1165-7. PubMed ID: 19137771
    [Abstract] [Full Text] [Related]

  • 15. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM, avec le soutien institutionnel du laboratoire Lilly.
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
    Ortonne JP, Chimenti S, Reich K, Gniadecki R, Sprøgel P, Unnebrink K, Kupper H, Goldblum O, Thaçi D.
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1012-20. PubMed ID: 21214631
    [Abstract] [Full Text] [Related]

  • 17. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.
    Thaçi D, Ortonne JP, Chimenti S, Ghislain PD, Arenberger P, Kragballe K, Saurat JH, Khemis A, Sprøgel P, Esslinger HU, Unnebrink K, Kupper H.
    Br J Dermatol; 2010 Aug; 163(2):402-11. PubMed ID: 20377585
    [Abstract] [Full Text] [Related]

  • 18. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update.
    Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Muller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B, Deutsche Dermatologische Gesellschaft (DDG), Berufsverband Deutscher Dermatologen (BVDD).
    J Dtsch Dermatol Ges; 2012 Mar; 10 Suppl 2():S1-95. PubMed ID: 22386073
    [Abstract] [Full Text] [Related]

  • 19. The two-compound formulation of calcipotriol and betamethasone dipropionate for treatment of moderately severe body and scalp psoriasis - an introduction.
    Freeman K.
    Curr Med Res Opin; 2011 Jan; 27(1):197-203. PubMed ID: 21142834
    [Abstract] [Full Text] [Related]

  • 20. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
    Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A.
    Br J Dermatol; 2008 Mar; 158(3):549-57. PubMed ID: 18047521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.